Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis

Documenti analoghi

• Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies
  di: Zhang, Lei, et al.
  Pubblicazione: (2020)
• Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS)
  di: Xu, Rong, et al.
  Pubblicazione: (2013)
• Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
  di: Raju Vaddepally, et al.
  Pubblicazione: (2022-03-01)
• The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
  di: Ke, Wanhai, et al.
  Pubblicazione: (2020)
• Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
  di: Kumar, Vivek, et al.
  Pubblicazione: (2017)